Abbott Laboratories (NYSE:ABT) Price Target Raised to $144.00

Key Points

• Abbott Laboratories has had its price target increased from $140.00 to $144.00 by Evercore ISI, indicating a potential upside of approximately 7.62% from its current stock price.
• The company reported a net margin of 32.43% and earnings per share (EPS) of $1.26 for the last quarter, aligning with analyst expectations and marking a year-over-year revenue increase of 7.4%.
• Institutional investors now hold 75.18% of Abbott Laboratories’ stock, highlighting significant confidence from major investment firms in the company's performance.

Abbott Laboratories (NYSE:ABT - Get Free Report) had its price objective lifted by equities research analysts at Evercore ISI from $140.00 to $144.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an "outperform" rating on the healthcare product maker's stock. Evercore ISI's price target suggests a potential upside of 7.62% from the company's current price.

Several other research analysts have also recently issued reports on ABT. Leerink Partners initiated coverage on Abbott Laboratories in a research report on Monday, June 16th. They issued a "market perform" rating and a $143.00 price objective for the company. The Goldman Sachs Group boosted their price objective on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a "buy" rating in a research report on Wednesday, October 1st. BTIG Research dropped their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a report on Friday, July 18th. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Finally, Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and raised their price objective for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $145.33.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT traded up $0.06 during trading on Tuesday, reaching $133.80. The company had a trading volume of 1,992,425 shares, compared to its average volume of 6,592,592. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The stock's fifty day moving average price is $132.08 and its 200 day moving average price is $131.44. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The firm has a market capitalization of $232.87 billion, a price-to-earnings ratio of 16.77, a price-to-earnings-growth ratio of 2.55 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion for the quarter, compared to analysts' expectations of $11.01 billion. During the same period in the previous year, the company posted $1.14 EPS. Abbott Laboratories's revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.46% of the stock is owned by insiders.

Institutional Trading of Abbott Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of the company. Norges Bank acquired a new stake in Abbott Laboratories in the second quarter worth about $3,026,180,000. Nuveen LLC bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $1,658,180,000. Laurel Wealth Advisors LLC raised its holdings in Abbott Laboratories by 13,347.0% during the second quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker's stock worth $823,804,000 after purchasing an additional 6,011,891 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Abbott Laboratories by 29.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 15,985,797 shares of the healthcare product maker's stock valued at $2,120,516,000 after acquiring an additional 3,616,471 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Abbott Laboratories by 12.8% in the 1st quarter. Wellington Management Group LLP now owns 29,763,415 shares of the healthcare product maker's stock valued at $3,948,117,000 after acquiring an additional 3,371,113 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.